NCT02448173Not yet recruitingPhase 3
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
OncoVAX® is the first cancer therapy that both prevents cancer recurrence and addresses the diversity of cancer cells. In this pivotal randomized, multicenter Phase IIIb study in patients with Stage II colon cancer, OncoVAX is designed to use a patient's own cancer cells to mobilize the body's immune system to prevent the return of colon cancer following surgery.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 550 (estimated)
- First submitted
- 6 May 2015
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Aug 2031
- Lead sponsor
- Vaccinogen Inc
- Diseases
- Colorectal cancer
- NCT number
- NCT02448173
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 550
- From 1 Aug 2026 to the primary completion date, 31 Aug 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with prior radiation therapy or chemotherapy or a prior malignancy of any type will be excluded. However, subjects with prior, curatively-treated squamous cell or basal cell carcinoma of the skin or carcinoma in situ of the cervix will be eligible for participation in this study.
- Patients with more than one malignant primary colon cancer will be excluded.
Who the study is looking for
- Patients must have Stage II (IIA = T3N0M0, IIB = T4aN0M0, IIC = T4bN0M0) disease.
- Patients must have undergone curative resection and have no evidence of residual or metastatic disease.
- Following curative resection patients must have a CEA within normal limits. If elevated prior to resection, it must return to normal within 21 days post surgery and prior to randomization.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Halifax Health Medical Center Coordinator of this site? Confirm its status | Port Orange | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.